Technology for extracting amino acids from residual medicine dregs generated in production of erythromycin

Abstract

The invention provides a technology for extracting amino acids from residual medicine dregs generated in the production of erythromycin. The technology comprises the following steps of: extracting the residual medicine dregs of erythromycin with deionized water and then carrying out filter pressing; distilling the solid obtained through filter pressing a lower temperature between150 and 200 DEG C, extracting amino acids from gas generated through distillation through a membrane method; firstly filtering filtrate obtained through filter pressing by using a metal membrane, mixing the filtered solid with the solid obtained through filter pressing and performing the above treatments, absorbing the filtrate obtained through metal membrane filtering by using ion exchange resin, eluting with alcoholic solvent and finally precipitating out and crystallizing clarithromycin by a control hydrolysis method, cleaning and centrifugalizing, performing vacuum drying on the solid obtained through centrifugalization to prepare clarithromycin; and separating and extracting amino acids from the liquid phase through the membrane method. By adopting the technology, the harmless application of fungus dregs can be realized and at least 10 tons of pure amino acid products can be extracted from 1000 tons of erythromycin fungus dregs; and the erythromycin content of the discharged waste treated by the technology provided by the invention is less than 1ppm, which completely meets the national discharge standard.

Description

technical field [0001] The invention relates to a process for extracting amino acids, in particular to a process for extracting amino acids by using erythromycin residues. Background technique [0002] The annual output of erythromycin API produced by fermentation in my country has reached a scale of 15,000 tons. The industry involves 17 large and small manufacturers from east to west, north, south, and north. The industry produces 100,000 tons (equivalent to dry matter) of medicinal residues (also called fungal residues) every year, and the undissolved mycelium in the medicinal residues accounts for about 30%wt of slag. Because erythromycin dregs contain active Streptomyces rubrum anti-phage and residual erythromycin (about 0.1%wt), it is listed as "hazardous solid waste" blacklist by the country. For decades, people have tried to recycle the dregs from the production of erythromycin, but all previous research work has revolved around the use of dregs rich in protein (18-...

AI Technical Summary

Problems solved by technology

For decades, people have tried to recycle the dregs from the production of erythromycin, but all previous research work has revolved around the use of dregs rich in protein (18-22%wt) to produce animal feed or the dregs Anaerobic fermentation is used to produce methane combustible gas. However, the residue of erythromycin (contained in feed and methane fermentation wastewater) and the inactivation of Streptomyces rubrum anti-phage strains cannot meet the national requirements.

Therefore, manufacturers now use the "dangerous goods landfill" method to dispose of the dregs after fermenting erythromycin, which easily pollutes the environment and also causes a huge waste of resources.

Images